IPCI's going to be Cash Flow Positive upon FDA approval of their pending FocalinXR strengths...and todays Q announcement clearly reflects that not only were the bio-studies costs absorbed in August...CEO Odidi specifically states that they're currently satisfying the FDA's Focalin bioequivalence requirements!
So considering Focalin bioequivalence only takes 60 days to complete...logic clearly suggests given the 2 clues provided this morning...that IPCI's on track to do the FocalinXR bioequivalence submission to the FDA b4 years end...and this is on a generic drug they've already received tentative approval on...so clearly the moment its submitted and bioequivalence is proven...it's not like the FDA can concoct any unforeseen out of left field further delay tactics...so the countdown's definitely begun on IPCI attaining CFP status...without even factoring any of their other 7 pending ANDA approvals, new licensing agreement announcements or possible Rexista global partner announcement!
So feel free to fear dilution...which flies completely in the face with CEO Odidi's proven extremely frugal track record of dilution over the last SEVERAL years...despite facing a never ending sequence of unforeseen hurdles, roadblocks, delays and challenges:)
News 
Market Data 
Discover 
